Fate Therapeutics/$FATE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Fate Therapeutics
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
Ticker
$FATE
Sector
Primary listing
Employees
181
Headquarters
Website
FATE Metrics
BasicAdvanced
$115M
-
-$1.45
2.24
-
Price and volume
Market cap
$115M
Beta
2.24
52-week high
$3.94
52-week low
$0.66
Average daily volume
1.5M
Financial strength
Current ratio
8.035
Quick ratio
7.89
Long term debt to equity
28.954
Total debt to equity
31.118
Profitability
EBITDA (TTM)
-161.605
Gross margin (TTM)
-1,260.99%
Net profit margin (TTM)
-2,025.05%
Operating margin (TTM)
-2,097.24%
Revenue per employee (TTM)
$50,000
Management effectiveness
Return on assets (TTM)
-24.66%
Return on equity (TTM)
-52.11%
Valuation
Price to revenue (TTM)
13.963
Price to book
0.44
Price to tangible book (TTM)
0.44
Price to free cash flow (TTM)
-0.996
Free cash flow yield (TTM)
-100.42%
Free cash flow per share (TTM)
-1.004
Growth
Revenue change (TTM)
-31.23%
Earnings per share change (TTM)
-14.22%
3-year revenue growth (CAGR)
-50.12%
10-year revenue growth (CAGR)
38.38%
3-year earnings per share growth (CAGR)
-18.11%
10-year earnings per share growth (CAGR)
0.84%
What the Analysts think about FATE
Analyst ratings (Buy, Hold, Sell) for Fate Therapeutics stock.
FATE Financial Performance
Revenues and expenses
FATE Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Fate Therapeutics stock?
Fate Therapeutics (FATE) has a market cap of $115M as of September 04, 2025.
What is the P/E ratio for Fate Therapeutics stock?
The price to earnings (P/E) ratio for Fate Therapeutics (FATE) stock is 0 as of September 04, 2025.
Does Fate Therapeutics stock pay dividends?
No, Fate Therapeutics (FATE) stock does not pay dividends to its shareholders as of September 04, 2025.
When is the next Fate Therapeutics dividend payment date?
Fate Therapeutics (FATE) stock does not pay dividends to its shareholders.
What is the beta indicator for Fate Therapeutics?
Fate Therapeutics (FATE) has a beta rating of 2.24. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.